Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the s...

Related Keywords

Massachusetts ,United States ,New York ,Garo Armen ,Advisory Inc ,Nasdaq ,Company Contact ,Protagenic Therapeutics Inc ,Clinical Stage ,Treatment Resistant Depression ,Generalized Anxiety Disorder ,Protagenic Therapeutics ,Clinical Trial ,Protocol Progress ,Generalized Anxiety ,Maurizio Fava ,Massachusetts General Hospital ,Principal Investigator ,Axiom Real Time Metrics ,Data Analytics ,Full Year ,Comprehensive Loss ,Access Code ,Corticotropin Releasing Factor ,Looking Statements ,Protagenic Therapeutic ,Chief Financial Officer ,Relations Contact ,